The effect of comorbidities on the choice of tyrosine kinase inhibitors in patients with chronic myeloid leukemia

Tyrosine kinase inhibitors (TKIs) approved for chronic myeloid leukemia known to have similar efficacies but different safety profiles. Therefore, the choice of patient-specific treatments is driven by factors such as tolerability and adverse event profile of TKIs. This review article examines the m...

Descripción completa

Detalles Bibliográficos
Autores principales: Saydam, Guray, Ali, Ridvan, Demir, Ahmet Muzaffer, Eskazan, Ahmet Emre, Guvenc, Birol, Haznedaroglu, Ibrahim Celalettin, Ozcan, Mehmet Ali, Salim, Ozan, Sonmez, Mehmet, Tuglular, Ayse Tulin, Turgut, Mehmet, Unal, Ali, Aver, Birkan, Bozkurt, Sirac, Ozdengulsun, Begum, Ilhan, Osman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9136639/
https://www.ncbi.nlm.nih.gov/pubmed/35664044
http://dx.doi.org/10.2217/ijh-2021-0010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9136639/
https://www.ncbi.nlm.nih.gov/pubmed/35664044
http://dx.doi.org/10.2217/ijh-2021-0010

Ejemplares similares